FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Fate Therapeutics
Bayer
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
BeOne Medicines
Janssen Research & Development, LLC
Boehringer Ingelheim
Novartis
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
Atavistik Bio, Inc
Novartis
Seagen Inc.
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Boehringer Ingelheim
Janssen Research & Development, LLC
Janssen Research & Development, LLC
ArriVent BioPharma, Inc.
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
Seagen Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Eli Lilly and Company
Janssen Research & Development, LLC
Pfizer
Janssen Research & Development, LLC
Pfizer
Janssen Research & Development, LLC
Servier
BeOne Medicines
Genentech, Inc.
Eisai Inc.
Novartis
Takeda
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
Hangzhou Sumgen Biotech Co., Ltd.
Eisai Inc.
Merck Sharp & Dohme LLC